Table 3.

Summary of studies evaluating the prognostic or predictive role of SLFN11 in ovarian cancer patients treated with platinum (P)-based chemotherapy or olaparib.

Type	Regime	n	Method	Results	Author [Reference]
cystadeno-carcinoma	P-based	110	IB	high SLFN11 expression independently predicts better OS	Zoppoli [24]
serous OC	P-based	41	M	SLFN11 hypermethylation was significantly associated with shorter OS and PFS	Nogales [25]
OC	P-based	110 (OS) 75 (DFS)	RNA-seq	high SLFN11 expression was associated with longer OS trend towards higher levels of SLFN11 expression in patients with DFS > 2y	Shee [20]
HGSC	P-based	28 (PFI) 221 (OS)	IHC	overall H-score in cancer and non-cancer cells was strongly associated with longer PFI SLFN11 is independently prognostic in the TCGA HGSC dataset	Winkler [49]
HGSC	P/T O maint	34 110	IHC	no significant link between SLFN11 levels and sensitivity to P/T trend towards longer PFS and OS in SLFN11-high patients high levels of SLFN11 associated with improved clinical outcome to olaparib	Willis [52]

Abbreviations: OC = ovarian cancer, HGSC = high-grade serous carcinoma, P = platinum, P/T = platinum-paclitaxel, O maint = olaparib maintenance, n = number of patients, OS = overall survival, DFS = disease-free survival, PFI = progression-free interval, IB = immunoblotting, M = methylation-specific PCR, IHC = immunohistochemistry, y = years, TCGA = The Cancer Genome Atlas.